Cardio Diagnostics (NASDAQ:CDIO) versus Precigen (NASDAQ:PGEN) Financial Comparison

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Precigen (NASDAQ:PGEN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cardio Diagnostics and Precigen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics 1 0 0 0 1.00
Precigen 1 1 4 0 2.50

Precigen has a consensus price target of $13.25, suggesting a potential upside of 214.73%. Given Precigen’s stronger consensus rating and higher possible upside, analysts plainly believe Precigen is more favorable than Cardio Diagnostics.

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cardio Diagnostics and Precigen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardio Diagnostics -40,543.75% -89.41% -82.81%
Precigen 15.55% 57.93% 14.43%

Earnings & Valuation

This table compares Cardio Diagnostics and Precigen”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardio Diagnostics $10,000.00 473.60 -$6.50 million ($2.53) -0.63
Precigen $9.68 million 155.94 -$250.64 million $0.10 42.10

Cardio Diagnostics has higher earnings, but lower revenue than Precigen. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cardio Diagnostics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Summary

Precigen beats Cardio Diagnostics on 11 of the 14 factors compared between the two stocks.

About Cardio Diagnostics

(Get Free Report)

Cardio Diagnostics Holdings, Inc. develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease. The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

About Precigen

(Get Free Report)

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.